Celltrion's 'Rekkirona' Administered at Residential Treatment Centers and Nursing Hospitals

Celltrion 'Rekkironaju' (Photo by Celltrion)

[Asia Economy Reporter Chunhee Lee] The administration of Celltrion's antibody treatment 'Rekkirona' will be expanded to more institutions.

On the morning of the 24th, Son Young-rae, head of the Social Strategy Division at the Central Disaster and Safety Countermeasures Headquarters, stated at a regular briefing, "Until now, the antibody treatment (Rekkirona injection) has been supplied to infectious disease specialized hospitals for patient treatment," adding, "From now on, the supply target will be expanded to administer the antibody treatment to mild and moderate patients at residential treatment centers and nursing hospitals."

This measure comes in response to the recent increase in confirmed cases and aims to strengthen treatment for mild and moderate patients. The eligible recipients are adult confirmed cases over 50 years old, or those with underlying conditions, or those showing signs of pneumonia, among mild patients who do not require oxygen therapy.

The supply will begin on the 25th. Nursing hospitals will receive supplies after each city and province assesses demand by nursing hospital. Residential treatment centers can apply directly to Celltrion for the medication and plan to administer it by installing separate injection rooms or utilizing cooperating hospitals.

This content was produced with the assistance of AI translation services.